Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Daiichi Sankyo
Accenture
Healthtrust
Colorcon
Queensland Health
Johnson and Johnson
Dow
Deloitte

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209394

« Back to Dashboard

NDA 209394 describes MAVYRET, which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the MAVYRET profile page.

The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
Summary for 209394
Tradename:MAVYRET
Applicant:Abbvie Inc
Ingredient:glecaprevir; pibrentasvir
Patents:4
Generic Entry Opportunity Date for 209394
Generic Entry Date for 209394*:
Constraining patent/regulatory exclusivity:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 209394
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394 NDA AbbVie Inc. 0074-2625 N 0074-2625-01
MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394 NDA AbbVie Inc. 0074-2625 N 0074-2625-28

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG;40MG
Approval Date:Aug 3, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 3, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Jan 19, 2032Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
Patent:➤ Try a Free TrialPatent Expiration:May 18, 2032Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Cantor Fitzgerald
Accenture
Cipla
Federal Trade Commission
Covington
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.